The Association Between Polycystic Ovary Syndrome and Vitamin D Deficiency in Infertile Women: A Case‑Control Study [Letter]
Hongjing Chen, Haobo Chen

Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsOvarian function and disorders · Vitamin D Research Studies · Reproductive tract infections research
Dear Editors,
We read with great interest the article titled “The Association Between Polycystic Ovary Syndrome and Vitamin D Deficiency in Infertile Women: A Case‑Control Study [1].” Polycystic ovary syndrome (PCOS) is characterized primarily by ovulatory dysfunction, hyperandrogenism, and polycystic ovarian morphology and constitutes a significant contributor to female infertility. Vitamin D deficiency is prevalent among women, and the authors offer novel insights by examining the association between vitamin D status and infertility in patients with PCOS. We would like to raise several points for clarification and further discussion that may help interpret the findings and guide future research.
First, the diagnostic criteria for infertility were not specified. This study enrolled women with PCOS and infertility, and reported the distribution of primary and secondary infertility. However, the diagnostic criteria for infertility were not clearly defined. According to the 2025 WHO guideline, infertility is defined as the failure to achieve pregnancy after 12 months or more of regular unprotected intercourse [2]. Clarifying this definition would improve the interpretability and comparability of the study population.
Second, although the authors reported a post hoc power analysis, the achieved sample size (66 per group) was smaller than the initially planned sample size. It would be helpful to further discuss how this deviation from the original sampling plan might influence the stability and generalizability of the estimated effect sizes, particularly in a multivariable model adjusting for several confounders.
Third, insulin resistance is a key pathophysiological feature of PCOS and is closely linked to both vitamin D status and metabolic outcomes [3]. While the authors appropriately acknowledged the absence of direct insulin resistance markers, such as HOMA‐IR, it would be informative to clarify whether any proxy indicators (e.g., history of diabetes or use of insulin‐sensitizing medications) were assessed or excluded [4, 5]. Explicitly addressing this point would help readers better understand the potential impact of residual confounding.
In summary, this study provides valuable local data on vitamin D deficiency in infertile women with PCOS. Clarification of infertility definitions, further discussion of sample size considerations, and a more detailed description of insulin‐related confounding would further strengthen the methodological transparency and clinical interpretability of the findings.
Author Contributions
Hongjing Chen: conceptualization, writing – original draft, writing – review and editing. Haobo Chen: writing – review and editing.
Funding
The authors received no specific funding for this work.
Conflicts of Interest
The authors declare no conflicts of interest.
The reference list from the paper itself. Each links out to its DOI / PubMed record.
- 1F. Yari , F. Janani , P. Baharvand , and A. Momeni , “The Association Between Polycystic Ovary Syndrome and Vitamin D Deficiency in Infertile Women: A Case‐Control Study,” Health Science Reports 8, no. 11 (2025): e 71553.41268360 10.1002/hsr 2.71553 PMC 12626901 · doi ↗ · pubmed ↗
- 2G. Mburu , N. Santesso , R. Brignardello‐Petersen , et al., “Recommendations From the WHO Guideline for the Prevention, Diagnosis, and Treatment of Infertility†,” Human Reproduction 41, no. 1 (2026): 25–38.41312724 10.1093/humrep/deaf 212PMC 12769440 · doi ↗ · pubmed ↗
- 3Y. Yang , Y. Han , J. Xu , Y. Gao , and B. He , “The Effects of Chiglitazar and Metformin on Insulin Resistance in Women With a Normal BMI and Polycystic Ovary Syndrome: A Randomized Controlled Study,” BMC Endocrine Disorders 25 (2025): 283.41331576 10.1186/s 12902-025-02082-0PMC 12746622 · doi ↗ · pubmed ↗
- 4W. T. Liao , J. Y. Huang , M. T. Lee , Y. C. Yang , and C. C. Wu , “Higher Risk of Type 2 Diabetes in Young Women With Polycystic Ovary Syndrome: A 10‐Year Retrospective Cohort Study,” World Journal of Diabetes 13, no. 3 (2022): 240–250.35432752 10.4239/wjd.v 13.i 3.240PMC 8984565 · doi ↗ · pubmed ↗
- 5J. P. Christ , O. Yu , B. Barton , et al., “Risk Factors for Incident Polycystic Ovary Syndrome Diagnosis,” Journal of Women's Health 33, no. 7 (2024): 879–886.10.1089/jwh.2023.074138557154 · doi ↗ · pubmed ↗
